You are here

Article info

Article menu

This article has a correction. Please see:

Basic tumor immunology
Original research
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity

Authors

  • Laura Fernandez-Rodriguez Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  • Chiara Cianciaruso Department of Pathology and Immunology, University of Geneva, Geneve, SwitzerlandAGORA Cancer Research Center, Lausanne, SwitzerlandCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Ruben Bill Department of Pathology and Immunology, University of Geneva, Geneve, SwitzerlandAGORA Cancer Research Center, Lausanne, SwitzerlandCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Marcel P Trefny Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  • Richard Klar Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany PubMed articlesGoogle scholar articles
  • Nicole Kirchhammer Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  • Mélanie Buchi Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  • Julia Festag Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany PubMed articlesGoogle scholar articles
  • Sven Michel Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany PubMed articlesGoogle scholar articles
  • Rainer H Kohler Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Elham Jones Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  • Andre Maaske Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany PubMed articlesGoogle scholar articles
  • Johannes vom Berg Institute of Laboratory Animal Science, University of Zurich, Zürich, Switzerland PubMed articlesGoogle scholar articles
  • Sebastian Kobold Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, GermanyGerman Center for Lung Research (DZL), German Center for Translational Cancer Research (DKTK), partner site Munich, Munich, Germany PubMed articlesGoogle scholar articles
  • Abhishek S Kashyap Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  • Frank Jaschinski Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany PubMed articlesGoogle scholar articles
  • Karen O Dixon Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  • Mikael J Pittet Department of Pathology and Immunology, University of Geneva, Geneve, SwitzerlandAGORA Cancer Research Center, Lausanne, SwitzerlandCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USALudwig Institute for Cancer Research Lausanne Branch, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Alfred Zippelius Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, SwitzerlandDepartment of Medical Oncology, University Hospital Basel, Basel, Switzerland PubMed articlesGoogle scholar articles

Citation

Fernandez-Rodriguez L, Cianciaruso C, Bill R, et al
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
Journal for ImmunoTherapy of Cancer 2023;11:e006714. doi: 10.1136/jitc-2023-006714
Online issue publication 
May 19, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.